Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dianicline 40 mg bid for smoking cessation (7-week, double-blind, placebo-controlled)
2006-001099-20Phase 3Completed
- Sponsor
- Sanofi
- Start
- Mar 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in nicotine dependence comparing Dianicline 40 mg bid with Placebo (2 arms). Primary endpoint: Four-week continuous abstinence from smoking (W4–W7). Started Mar 2006; status: completed.
02
Drugs
dianicline
03
Conditions
nicotine dependence
Beyond the preview
Go deeper on 2006-001099-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-001099-20.